Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management

Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia

(2016) Joshua N. Gustine et al.   AMERICAN JOURNAL OF HEMATOLOGY

The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis

(2016) Darryl P. Leong et al.   BLOOD

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study

(2016) Philip A. Thompson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling

(2016) L de Zwart et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

(2016) C. S. Tam et al.   HAEMATOLOGICA

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

(2016) Jingjing Wu et al.   Journal of Hematology & Oncology

Wytyczne ESC dotyczące leczenia migotania przedsionków w 2016 roku, opracowane we współpracy z EACTS

(2016) Paulus Kirchhof et al.   Kardiologia Polska

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

(2016) Martin Dreyling et al.   LANCET

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

(2016) Asher Chanan-Khan et al.   LANCET ONCOLOGY

Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice

(2016) Heidi D. Finnes et al.   LEUKEMIA & LYMPHOMA

Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma

(2016) Hun Ju Lee et al.   LEUKEMIA & LYMPHOMA

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)

(2016) Tait D. Shanafelt et al.   LEUKEMIA & LYMPHOMA

The State of the Art

(2016) Daniel P. Morin et al.   MAYO CLINIC PROCEEDINGS

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

(2016) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1

(2016) Raed A. Joundi et al.   STROKE

Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

(2016) C. S. Tam et al.   HAEMATOLOGICA

Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial

(2015) Christopher B. Granger et al.   AMERICAN HEART JOURNAL

Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib

(2015) J. C. Byrd et al.   BLOOD

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

(2015) H. S. Walter et al.   BLOOD

Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib

(2015) J. C. Byrd et al.   BLOOD

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

(2015) P. Jain et al.   BLOOD

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

(2015) M. L. Wang et al.   BLOOD

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

(2015) A. H. Lipsky et al.   HAEMATOLOGICA

Idarucizumab for Dabigatran Reversal

(2015) Charles V. Pollack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

(2015) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

(2015) A. H. Lipsky et al.   HAEMATOLOGICA

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

(2015) Kami J. Maddocks et al.   JAMA Oncology

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions

(2014) M. Levade et al.   BLOOD

Ibrutinib inhibits BCR and NF- B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

(2014) S. E. M. Herman et al.   BLOOD

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling

(2014) J. R. McMullen et al.   BLOOD

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

(2014) J. A. Woyach et al.   BLOOD

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

(2014) Jan A Burger et al.   LANCET ONCOLOGY

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

(2014) S Kamel et al.   LEUKEMIA

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

(2013) J. A. Dubovsky et al.   BLOOD

Worldwide Epidemiology of Atrial Fibrillation

(2013) Sumeet S. Chugh et al.   CIRCULATION

All-cause mortality in 272 186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case–control study

(2013) Tommy Andersson et al.   EUROPEAN HEART JOURNAL

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

(2013) Christian T Ruff et al.   LANCET

Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phosphoinositide 3-Kinase p110α Is a Master Regulator of Exercise-Induced Cardioprotection and PI3K Gene Therapy Rescues Cardiac Dysfunction

(2012) Kate L. Weeks et al.   Circulation-Heart Failure

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

(2010) Ron Pisters et al.   CHEST

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reduced Phosphoinositide 3-Kinase (p110α) Activation Increases the Susceptibility to Atrial Fibrillation

(2009) Lynette Pretorius et al.   AMERICAN JOURNAL OF PATHOLOGY

Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach

(2009) Gregory Y.H. Lip et al.   CHEST